retatrutide weight loss phase 2 trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished First Retatrutide phase 3 data,

Patients with certain genetic predispositions may see faster appetite suppression regardless of injection timing, while others might benefit from strategic scheduling around their eating patterns

2022;379:e071380

Indeed, N-acetylgalactosamine-conjugated siRNA targeting AGT was highly effective in suppressing circulating AGT, thereby reducing blood pressure as ACE-inhibitors (ACE-i) and angiotensin-II receptor blockers (ARBs) (45)

Additionally, these medications have been shown to modestly reduce blood pressure and improve lipid profiles, further supporting cardiovascular health

It is a dual GLP-1/glucagon receptor agonist